Risk factors for blindness in patients with open-angle glaucoma followed-up for at least 15 years

Arquivos Brasileiros de Oftalmologia

Volumn 75, Issue 4, 2012, Pages 243-246

  Paula, Jayter Silva ^a   Furtado, João Marcello ^a   Santos, Arles Silva ^a   De Mattos Coelho, Roberto ^a   Rocha, Eduardo Melani ^a   De Lourdes Veronese Rodrigues, Maria ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Blindness etiology; Glaucoma; Open angle therapy; Open angle complications; Optic disk physiopathology; Risk factors; Visual acuity

Indexed keywords

EID: 84872242324     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492012000400004     Document Type: Article

References (25)

1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: Results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10): 1268-79. Comment in: Arch Opthalmol. 2002;120(10):1371-2; JAMA. 2002;288(20): 2607-8; Optom Vis Sci. 2002;79(121):741-2.
2. Van Buskirk EM, Cioffi GA. Glaucomatous optic neuropathy. Am J Ophthalmol. 1992; 113(4):447-52.
3. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996; 80(5):389-93.
4. Schwartz GF. Persistency and tolerability of ocular hypotensive agents: populationbased evidence in the management of glaucoma. Am J Ophthalmol. 2004;137( 1 Suppl): S1-2. Comment in: Am J Opthalmol. 2004;1093-4; author reply 1094.
5. Friedman DS, Hahn SR, Gelb L, Tan J, Shah SN, Kim EE, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the glaucoma adherence and persistency study. Ophthalmology. 2008;115(8):1320-7.
6. Quigley HA, Tielsch JM, Katz J, Sommer A. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol. 1996; 122(3):355-63. Comment in: Am J Ophthalmol. 1997;123(3):426-8.
7. Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO, Yawn BP, et al. The probability of blindness from open-angle glaucoma. Ophthalmology. 1998; 105(11):2099-104. Comment in: Ophthalmology. 1999;106(11):2039-41.
8. Shirakashi M, Iwata K, Sawaguchi S, Abe H, Nanba K. Intraocular pressure- dependent progression of visual field loss in advanced primary open-angle glaucoma: a 15-year follow-up. Ophthalmologica. 1993;207(1):1-5.
9. Zeyen TG, Caprioli J. Progression of disc and field damage in early glaucoma. Arch Ophthamol. 1993;111(1):62-5.
10. Arruda Mello PA, Mandia Jr C, editores. 2° Consenso Brasileiro de Glaucoma Primário de Ângulo Aberto. São Paulo: PlanMark; 2005. p.12.
11. Anderson DR. Automated static perimetry. St. Louis: Mosby; 1992.
12. Chen PP. Correlation of visual field progression between eyes in patients with chronic open angle glaucoma. Ophthalmology 2002;109(11):2093-9.
13. Spaeth GL, Hwang S, Gomes M. Disc damage as a prognostic and therapeutic consideration in the management of patients with glaucoma. In: Gramer E, Grehn F, editors. Pathogenesis and risk factors of glaucoma. Berlin: Springer; 1999. p.135-44.
14. Eid TM, Spaeth GL, Bitterman A, Steinmann WC. Rate and amount of visual loss in 102 patients with open-angle glaucoma followed up for at least 15 years. Ophthalmology. 2003;110(5):900-7.
15. Chen PP. Blindness in patients with treated open-angle glaucoma. Ophthalmology. 2003;110(4):726-33. Comment in: Ophthalmology. 2003;110(4):634-5.
16. Kim J, Dally LG, Ederer F, Gaasterland DE, VanVeldhuisen PC, Blackwell B, et al. The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing progression of glaucoma from visual field fluctuations. Ophthalmology. 2004;111(11):2109-16.
17. Kobelt G, Jonsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol. 1998;236(11):811-21
18. Florentinus SR, van Hulten R, Kloth ME, Heerdink ER, Griens AM, Leufkens HG, groenewegen PP; Netherlands Institute for Health Services Research. The effect of pharmacotherapy audit meetings on early new drug prescribing by general practitioners. Ann Pharmacother. 2007;41(12):319-24.
19. Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002;18(5):401-9.
20. Realini T, Fechtner RD. 56,000 ways to treat glaucoma. Ophthalmology 2002;109:1955-6.
21. Jönsson B. The health economics of glaucoma. In: Jönsson B, Kriegltstein G, editors. Primary open-angle glaucoma: differences in international treatment patterns and costs. Oxford: Isis Medical Media; 1999. p.1-9.
22. Grant WM, Burke JF Jr. Why do some people go blind from glaucoma? Ophthalmology. 1982;89(9):991-8.
23. Gullo RM, Costa VP, Bernardi L, Kara-José N. Visual conditions of glaucomatous patients in an university hospital. Arq Bras Oftalmol.1996;59(2):147-50.
24. Demarco AL, Rodrigues ML, Demarco LA. Ophthalmologic profile of patients going into the glaucoma wing of an university service. Medicina. 2002;35:478-86.
25. Oliveira A, Paranhos A Jr, Prata JA Jr. Characteristics presented by patients on their first appointment at the glaucoma sector of Universidade Federal de São Paulo - UNIFESP. Arq Bras Oftalmol. 2003;66(6):785-90.